X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PANACEA BIOTECH - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PANACEA BIOTECH SUN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 35.1 -6.3 - View Chart
P/BV x 2.7 1.9 145.7% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
PANACEA BIOTECH
Mar-14
SUN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs701149 471.1%   
Low Rs43382 526.4%   
Sales per share (Unadj.) Rs110.484.1 131.2%  
Earnings per share (Unadj.) Rs11.0-18.3 -60.0%  
Cash flow per share (Unadj.) Rs17.2-6.7 -257.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.883.7 189.7%  
Shares outstanding (eoy) m2,399.2661.25 3,917.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.4 374.0%   
Avg P/E ratio x51.6-6.3 -818.5%  
P/CF ratio (eoy) x32.9-17.2 -190.8%  
Price / Book Value ratio x3.61.4 258.7%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0217,074 19,224.6%   
No. of employees `00017.82.8 646.9%   
Total wages/salary Rs m53,6711,449 3,703.5%   
Avg. sales/employee Rs Th14,890.91,874.1 794.6%   
Avg. wages/employee Rs Th3,017.1527.0 572.5%   
Avg. net profit/employee Rs Th1,480.6-407.7 -363.1%   
INCOME DATA
Net Sales Rs m264,8955,154 5,139.9%  
Other income Rs m8,388100 8,404.4%   
Total revenues Rs m273,2825,254 5,201.9%   
Gross profit Rs m56,081-766 -7,318.5%  
Depreciation Rs m14,998711 2,109.5%   
Interest Rs m5,1761,503 344.4%   
Profit before tax Rs m44,295-2,881 -1,537.7%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-9,5051,771 -536.7%   
Tax Rs m8,45217 50,308.9%   
Profit after tax Rs m26,338-1,121 -2,348.9%  
Gross profit margin %21.2-14.9 -142.4%  
Effective tax rate %19.1-0.6 -3,271.6%   
Net profit margin %9.9-21.8 -45.7%  
BALANCE SHEET DATA
Current assets Rs m316,3593,810 8,302.9%   
Current liabilities Rs m198,6438,365 2,374.6%   
Net working cap to sales %44.4-88.4 -50.3%  
Current ratio x1.60.5 349.7%  
Inventory Days Days95156 60.9%  
Debtors Days Days10867 160.2%  
Net fixed assets Rs m213,17814,480 1,472.2%   
Share capital Rs m2,39961 3,914.0%   
"Free" reserves Rs m378,606903 41,923.0%   
Net worth Rs m381,0065,127 7,431.1%   
Long term debt Rs m17,7215,832 303.9%   
Total assets Rs m643,02819,433 3,308.9%  
Interest coverage x9.6-0.9 -1,042.9%   
Debt to equity ratio x01.1 4.1%  
Sales to assets ratio x0.40.3 155.3%   
Return on assets %4.92.0 249.5%  
Return on equity %6.9-21.9 -31.6%  
Return on capital %10.03.6 275.6%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m40,8161,539 2,651.8%   
Fx outflow Rs m30,143942 3,199.9%   
Net fx Rs m10,673597 1,787.2%   
CASH FLOW
From Operations Rs m39,072599 6,520.6%  
From Investments Rs m-33,708-438 7,697.7%  
From Financial Activity Rs m-15,393-303 5,086.8%  
Net Cashflow Rs m-7,359-141 5,208.1%  

Share Holding

Indian Promoters % 63.7 74.5 85.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.6 855.0%  
FIIs % 23.0 1.3 1,769.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 23.6 35.2%  
Shareholders   133,026 10,259 1,296.7%  
Pledged promoter(s) holding % 0.5 35.1 1.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Dec 12, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS